Get access

CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant

Authors

  • Roberto J. Firpi,

    Corresponding author
    • Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Huijia Dong,

    1. Department of Pathology, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Virginia C. Clark,

    1. Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Consuelo Soldevila-Pico,

    1. Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Giuseppe Morelli,

    1. Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Roniel Cabrera,

    1. Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Oxana Norkina,

    1. Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Jonathan J. Shuster,

    1. Department of Health Outcomes and Policy College of Medicine, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • David R. Nelson,

    1. Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
    • Nelson and Liu share the senior authorship.
  • Chen Liu

    1. Department of Pathology, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
    • Nelson and Liu share the senior authorship.

Correspondence

Roberto J. Firpi, University of Florida, Section of Hepatobiliary Diseases, 1600 SW Archer Rd, Room M440 MSB, P.O. Box 100277, JHMHC, Gainesville, Florida 32610-0214

Tel: +352-273-9466

Fax: +352-392-7393

e-mail: Roberto.Firpi@medicine.ufl.edu

Abstract

Background/Aims

Interleukin-28B (IL-28B) polymorphism is the strongest pretreatment predictor of viral clearance in the hepatitis C (HCV) population. Donor and recipient IL-28B genomic background may play an important role in post-transplant HCV recurrence. We sought to examine the role of IL-28B polymorphisms of donor and recipients in liver transplant patients with recurrent HCV and its impact on the response to interferon-based therapy.

Methods

The cohort study consisted of 135 adult liver transplant patients who received interferon-based therapy for recurrent HCV between 1996 and 2005 at the University of Florida. IL-28B single nucleotide polymorphism (rs. 12979860) was characterized using liver tissue from all donors and recipients.

Results

The CC genotype was observed in approximately 30% of donors and recipients. Sustained viral response (SVR) to HCV therapy was 100% if both recipient and donor were CC genotype, while the SVR was only 25% if neither donor nor recipient had a CC genotype. (Recipient, = 0.025, Donor, < 0.001). Recipients and donors with CC genotype had less fibrosis than recipients with genotypes CT and TT, but the difference was not statistically significant. IL-28B genotype did not seem to play a role in the overall survival in these patients.

Conclusion

In conclusion, recipient and donor CC genotype is associated with a better treatment response to interferon-based therapy after liver transplant. Our study suggests that using CC genotype donor livers for HCV patients may improve the overall clinical outcome after liver transplantation.

Ancillary